Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon α: Involvement of tumor necrosis factor as ligand for the CD95 receptor

Blood

Volumn 97, Issue 9, 2001, Pages 2791-2797

  Gisslinger, Heinz ^a,b,c   Kurzrock, Razelle ^a,b   Gisslinger, Bettina ^a,b   Jiang, Shuwei ^a,b   Li, Shuren ^a,b   Virgolini, Irene ^a,b   Woloszczuk, Wolfgang ^a,b   Andreeff, Michael ^a,b   Talpaz, Moshe ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD95 RECEPTOR; FAS LIGAND; RECOMBINANT ALPHA2A INTERFERON; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BURKITT LYMPHOMA; CELL DEATH; CONTROLLED STUDY; DAUDI CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 0035353199     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2791     Document Type: Article

References (44)

1. McDonnell TJ. Cell division versus cell death: a functional model of multistep neoplasia. Mol Carcinog. 1993;8:209-213.
2. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1-6.
3. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233-243.
4. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245:301-305.
5. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell. 1995;81:479-482.
6. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169:1747-1756.
7. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 1995;373:441-444.
8. Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today. 1992;13:427-428.
9. Clemens MJ. Molecular mechanisms of interferon action. Br J Clin Pract. 1988;62(suppl):5-12.
10. Kurzrock R, Quesada JR, Talpaz M, et al. Phase I study of multiple-dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986;4:1101-1109.
11. Levy D, Lamer A, Chaudhuri A, Babiss LE, Darnell JE Jr. Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci U S A. 1986;83:8929-8933.
12. Larner AC, Chaudhuri A, Darnell JE Jr. Transcriptional induction by interferon: new protein(s) determine the extent and length of the induction. J Biol Chem. 1986;261:453-459.
13. Kelly JM, Porter AC, Chernajovsky Y, Gilbert CS, Stark GR, Kerr IM. Characterization of a human gene inducible by alpha- and beta-interferons and its expression in mouse cells. EMBO J. 1986;5:1601-1606.
14. Clemens M. Cell proliferation: interferons and oncogenes. Nature. 1985;313:531-532.
15. Kumar R, Atlas I. Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci U S A. 1992;89:6599-6603.
16. Milner AE, Grand RJ, Waters CM, Gregory CD. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene. 1993;8:3385-3391.
17. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89:957-964.
18. Seileri C, Maciejewski JP, Pane F, et al. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 1998;92:981-989.
19. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998;16:1526-1531.
20. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989;i:634-637.
21. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-a) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol. 1996;92:55-59.
22. Smalley RV, Connors J, Tuttle RL, Anderson S, Robinson W, Whisnant JK. Splenectomy vs alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol. 1992;41:13-18.
23. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol. 1996;156:18-21.
24. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
25. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
26. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z. Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry. 1994;15:237-244.
27. Virgolini I, Raderer M, Kurtaran A, et al. Vasocative intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116-1121.
28. Scatchard G. The attractions of proteins for small molecules and ions. Am N Y Acad Sci. 1949;51:660.
29. Suzuki A, Tsutomi Y, Shimizu M, Matsuzawa A. Another cell death induction system: TNF-a acts as a ligand for fas in vaginal cells. Cell Death Differ. 1999;6:638-643.
30. Racila E, Hsueh R, Marches R, et al. Tumor dormancy and cell signaling: anti-m-induced apoptosis in human B-lymphoma cells is not caused by an APO-1-APO-1 ligand interaction. Proc Natl Acad Sci U S A. 1996;93:2165-2168.
31. Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279:1954-1958.
32. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296-300.
33. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998;17:706-718.
34. Zornig M, Hueber AO, Evan G. p53-Dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol. 1998;8:467-470.
35. Schlegel J, Peters I, Orrenius S, et al. CPP32/ apopain is a key interieukin-1-beta-converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem. 1996;271:1841-1844.
36. Tomita Y, Kawasaki T, Bilim V, Takeda M, Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer. 1996;68:132-135.
37. Bernassola F, Scheuerpflug CH, Herr I, Krammer PH, Debatin KM, Melino G. Induction of apoptosis by IFNγ in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. Cell Death Differ. 1999;6:652-660.
38. Yanase N, Takada E, Yoshihama I, Ikegami H, Mizuguchi J. Participation of Bax-a in IFN-α-mediated apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 1998;18:855-861.
39. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem. 1999;274:2225-2233.
40. Kluck RM, Martin SJ, Hoffman BM, Zhou JS, Green DR, Newmeyer DD. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J. 1997;16:4639-4649.
41. Kitanaka CH, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ. 1999;6:508-515.
42. + cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-252.
43. Nagafuji K, Shibuya T, Harada M, et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 1995;86:883-889.
44. + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183-3190.